Helicobacter pylorieradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: Systematic review and meta-analysis of randomised controlled trials

BMJ (Online)

Volumn 348, Issue , 2014, Pages

  Ford, Alexander C ^a,b   Forman, David ^c   Hunt, Richard H ^d   Yuan, Yuhong ^d   Moayyedi, Paul ^d  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROIMIDAZOLE; AMOXICILLIN; BISMUTH SALT; CLARITHROMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; MACROLIDE; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE; TETRACYCLINE;

ARTICLE; ASYMPTOMATIC INFECTION; CANCER INCIDENCE; CANCER PREVENTION; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; ERADICATION THERAPY; ESOPHAGUS CANCER; EVIDENCE BASED MEDICINE; HELICOBACTER INFECTION; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER; SYSTEMATIC REVIEW; DISEASE ERADICATION; HELICOBACTER PYLORI; MICROBIOLOGY; REVIEW; STOMACH TUMOR; TREATMENT OUTCOME;

ASYMPTOMATIC INFECTIONS; DISEASE ERADICATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS;

EID: 84901390048     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g3174     Document Type: Article

References (60)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012, version 1.0: Cancer incidence and mortality worldwide. IARC CancerBase No 11. International Agency for Research on Cancer; 2013. Available from http:globocan. iarc.fr.
2. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol 2012;13:790-801.
3. Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;321:1273-5.
4. Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfill Koch's postulates for pyloric Campylobacter. Med J Aust 1985;142:436-9. (Pubitemid 15233564)
5. Correa P. The gastric precancerous process. Cancer Surv 1983;2:437-50.
6. Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. Lancet 1975;306:58-60.
7. Nomura A, Stemmerman GN, Chyou P-H, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991;325:1132-6.
8. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991;325:1127-31.
9. Forman D, Newell DG, Fullerton F, Yarnell JWG, Stacey AR, Wald N, et al. Association between infection with Helicobacter pylori and risk of gastric cancer: Evidence from a prospective investigation. BMJ 1991;302:1302-5.
10. International Agency for Research on Cancer. Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994;61:177-241.
11. Parsonnet J, Harris RA, Hack HM, Owens DK. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: A mandate for clinical trials. Lancet 1996;348:150-4. (Pubitemid 26238097)
12. Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, et al. Meta-analysis: Can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009;151:121-8.
13. Ford AC, Moayyedi P. Redundant data in the meta-analysis on Helicobacter pylori eradication. Ann Intern Med 2009;151:513.
14. Moayyedi P, Hunt R, Forman D. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev 2006; (1): CD005583.
15. Akl EA, Johnston BC, Alonso-Coello P, Neumann I, Ebrahim S, Briel M, et al. Addressing dichotomous data for participants excluded from trial analysis: A guide for systematic reviewers. PLoS One 2013;8:e57132.
16. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.0.2. 2009. www.cochrane-handbook.org.
17. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. (Pubitemid 17189972)
18. International Agency for Research on Cancer. GLOBOCAN 2008. Estimated cancer incidence, mortality, prevalence and disability-adjusted life years (DALYs) worldwide in 2008. 2008. http://globocan. iarc.fr/.
19. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. (Pubitemid 37088507)
20. Egger M, Davey-Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34. (Pubitemid 27387172)
21. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002.
22. Correa P, Fontham ETH, Bravo JC, Bravo LE, Ruiz B, Zarama G, et al. Chemoprevention of gastric dysplasia: Randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000;92:1881-8. (Pubitemid 32036918)
23. Saito D, Boku N, Fujioka T, Fukuda Y, Matsushima Y, Sakaki N, et al. Impact of H. pylori eradication on gastric cancer prevention: Endoscopic results of the Japanese intervention trial (JITHP-Study): A randomized multi-center trial. Gastroenterology 2005;128(suppl 2):A4.
24. Wong BCY, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: A randomized controlled trial. JAMA 2004;291:187-94. (Pubitemid 38082812)
25. Wong BCY, Zhang L, Ma J-L, Pan K-F, Li J-Y, Shen L, et al. Effects of selective COX-2 inhibition and Helicobacter pylori eradication on precancerous gastric lesions. Gut 2012;61:812-8.
26. Ma J-L, Zhang L, Brown LM, Li J-Y, Shen L, Pan K-F, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst 2012;104:488-92.
27. Zhou L. Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China. Gastroenterology 2008;134(suppl 1):A233.
28. Leung WK, Lin S-R, Ching JYL, To K-F, Ng EKW, Chan FKL, et al. Factors predicting progression of gastric intestinal metaplasia: Results of a randomised trial on Helicobacter pylori eradication. Gut 2004;53:1244-9. (Pubitemid 39120105)
29. Mera R, Fontham ETH, Bravo LE, Bravo JC, Piazuelo MB, Camargo MC, et al. Long-term follow-up of patients treated for Helicobacter pylori infection. Gut 2005;54:1536-40. (Pubitemid 41531767)
30. Ruiz B, Garay J, Correa P, Fontham ETH, Bravo JC, Bravo LE, et al. Morphometric evaluation of gastric antral atrophy: Improvement after cure of Helicobacter pylori infection. Am J Gastroenterol 2001;96:3281-7. (Pubitemid 34016649)
31. Sung JJY, Lin S-R, Ching JYL, Zhou L-Y, To KF, Wang R-T, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: A prospective, randomized study. Gastroenterology 2000;119:7-14. (Pubitemid 30452573)
32. You W-C, Brown LM, Zhang L, Li J-Y, Jin M-L, Chang Y-S, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006;98:974-83. (Pubitemid 44288162)
33. Zhou L, Sung JJ, Lin S, Jin Z, Ding S, Huang X, et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chin Med J 2003;116:11-4. (Pubitemid 36432713)
34. Zhou L. Eight-year follow-up study on the morbidity of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication. Gastroenterology 2005;128(suppl 2):A16.
35. Correa P, Fontham ETH, Bravo JC, Bravo LE, Ruiz B, Zarama G, et al. Chemoprevention of gastric dysplasia: Randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. Reply. J Natl Cancer Inst 2001;93:559-60.
36. Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, et al. The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol 2005;100:1037-42. (Pubitemid 40769039)
37. Hamajima N, Matuo K, Watanabe Y, Suzuki T, Nakamura T, Matsuura A, et al. A pilot study to evaluate stomach cancer risk reduction by Helicobacter pylori eradication. Am J Gastroenterol 2002;97:764-5. (Pubitemid 34245918)
38. Hsu P-I, Lai K-H, Hsu P-N, Lo G-H, Yu H-C, Chen W-C, et al. Helicobacter pylori infection and the risk of gastric cancer. Am J Gastroenterol 2007;102:725-30. (Pubitemid 46496631)
39. Juibari M, Moayyedi R, Gholampour M, Bijarchi R, Peter K, Koucharian C, et al. Risk of precancerous pathologic changes in the stomach after appropriate eradication of Helicobacter pylori: A multi-centric study from a developing country. Gut 2003;52(suppl VI):A148.
40. Ohkusa T, Fujiki K, Takashimuzu I, Kumagai J, Tanizawa T, Eishi Y, et al. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med 2001;134:380-6. (Pubitemid 32179477)
41. Kamangar F, Dawsey SM, Blaser MJ, Perez-Perez GI, Pietinen P, Newschaffer CJ, et al. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst 2006;98:1445-52. (Pubitemid 44605589)
42. Harvey RF, Lane JA, Murray LJ, Harvey IM, Donovan JL, Nair P. Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol Helicobacter project. Br Med J 2004;328:1417-20.
43. Moayyedi P, Feltbower R, Brown J, Mason S, Mason J, Nathan J, et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: A randomised controlled trial. Lancet 2000;355:1665-9. (Pubitemid 30248477)
44. Wildner-Christensen M, Moller Hansen J, Schaffalitzky De Muckadell O. Rates of dyspepsia one year after Helicobacter pylori screening and eradication in a Danish population. Gastroenterology 2003;125:372-9. (Pubitemid 36929417)
45. Fischbach LA, Correa P, Ramirez H, Realpe JL, Collazos T, Ruiz B, et al. Anti-inflammatory and tissue-protectant drug effects: Results from a randomized placebo-controlled trial of gastritis patients at high risk for gastric cancer. Aliment Pharmacol Ther 2001;15:831-41. (Pubitemid 32500429)
46. Miehlke S, Kirsch C, Dragosics B, Gschwantler M, Oberhuber G, Antos D, et al. Helicobacter pylori and gastric cancer: Current status of the Austrian Czech German gastric cancer prevention trial (PRISMA-Study). World J Gastroenterol 2001;7:243-7. (Pubitemid 32377478)
47. Ford AC, Forman D, Bailey AG, Axon ATR, Moayyedi P. A community screening program for Helicobacter pylori saves money: Ten-year follow-up of a randomised controlled trial. Gastroenterology 2005;129:1910-7. (Pubitemid 41772968)
48. Lane JA, Murray LJ, Noble S, Egger M, Harvey IM, Donovan JL, et al. Impact of Helicobacter pylori eradication on dyspepsia, health resource use, and quality of life in the Bristol Helicobacter project: Randomised controlled trial. BMJ 2006;332:199-202. (Pubitemid 43171698)
49. Mason J, Axon ATR, Forman D, Duffett S, Drummond M, Crocombe W, et al. The cost-effectiveness of population Helicobacter pylori screening and treatment: A Markov model using economic data from a randomised controlled trial. Aliment Pharmacol Ther 2002;16:559-68. (Pubitemid 34214537)
50. Imanzadeh F, Sayyari AA, Akbari MR. Histopathology of the stomach mucosa after treatment for Helicobacter pylori: A multi-centric study. Gut 2004;53(suppl VI):A292.
51. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: An open-label, randomised controlled trial. Lancet 2008;372:392-7.
52. Choi J, Kim SG, Yoon H, Im JP, Kim JS, Kim WH, et al. Eradication of Helicobacter pylori after endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma. Clin Gastroenterol Hepatol 2014;12:793-800.
53. Fischbach LA, Bravo LE, Zarama GR, Bravo JC, Ojha PR, Priest EL, et al. A randomized clinical trial to determine the efficacy of regimens containing clarithromycin, metronidazole, and amoxicillin among histologic subgroups for Helicobacter pylori in a developing country. Helicobacter 2009;14:100-8.
54. Gail MH, You WC, Chang YS, Zhang L, Blot WJ, Brown LM, et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: Design issues and initial data. Control Clin Trials 1998;19:352-69. (Pubitemid 28355759)
55. Bazzoli F, Zagari RM, Fossi S, Pozzato P, Alampi G, Simoni P, et al. Short-term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994;6:773-7. (Pubitemid 24261052)
56. Correa P, Cuello C, Dugue E, Burbano LC, Garcia FT, Bolanos O, et al. Gastric cancer in Colombia III: Natural history of precursor lesions. J Natl Cancer Inst 1976;57:1027-35.
57. Lee Y-C, Chen TH-H, Chiu H-M, Shun C-T, Chiang H, Liu T-Y, et al. The benefit of mass eradication of Helicobacter pylori infection: A community-based study of gastric cancer prevention. Gut 2013;62:676-82.
58. Areia M, Carvalho R, Cadime AT, Rocha Goncalves F, Dinis-Ribeiro M. Screening for gastric cancer and surveillance of premalignant lesions: A systematic review of cost-effectiveness studies. Helicobacter 2013;18:325-37.
59. Harvey RF, Lane JA, Nair P, Egger M, Harvey I, Donovan J, et al. Clinical trial: Prolonged beneficial effect of Helicobacter pylori eradication on dyspepsia consultations-The Bristol Helicobacter Project. Aliment Pharmacol Ther 2010;32:394-400.
60. Talley NJ, Fock KM, Moayyedi P. Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. Am J Gastroenterol 2008;103:510-4.